



FOR IMMEDIATE RELEASE

Contact: Bruce Van Deman, NeoChord, Inc. (952) 698-7812; bvandeman@neochord.com

J. Alex Martin Joins NeoChord Board of Directors

ST. LOUIS PARK, Minn., United States – 4 April 2016 – NeoChord, announced today the appointment of J. Alex Martin to its Board of Directors. A 40-year, veteran corporate executive of the healthcare and medical device industries, Mr. Martin brings a proven track record for growing corporate revenue and successfully transforming global businesses.

“Alex’s strong accomplishments in sales and marketing leadership, U.S. and OUS regulatory expertise, along with his success in driving exits with large organizations are compelling reasons to ask him to join the Board,” states David Chung, NeoChord President and Chief Executive Officer. “Alex is a great addition to our already active Board”.

“I’m honored by this opportunity to join NeoChord’s Board of Directors,” said Martin. “The company is growing quickly; it’s an exciting time given the momentum in the development of minimally invasive technologies for the treatment of structural heart disease.”

Most recently, Mr. Martin was the President and CEO of Coherex Medical, where he led the company to a successful exit with Biosense Webster (a Johnson and Johnson company), in November 2015. Prior to Coherex, Mr. Martin was the President and CEO of WorldHeart Corporation, where he led the company to a successful exit with HeartWare in August 2012. Previously, Mr. Martin has held senior leadership roles with Edwards Lifesciences, Cordis Corporation (a Johnson & Johnson Company), and SonaMed Corporation. Mr. Martin’s educational background includes degrees from the University of Kentucky and University of Louisville, School of Medicine.

Based in St. Louis Park, Minn., NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair of DMR. Mitral regurgitation is a progressive disease that can result in atrial fibrillation, congestive heart failure, and death when left untreated. NeoChord received CE market clearance in December 2012 for the DS1000 system for minimally invasive mitral valve repair of degenerative mitral regurgitation without the use of cardiopulmonary bypass. To date, over 350 patients have been treated. For more information, visit: www.NeoChord.com.

*The NeoChord DS1000 System is CE marked and approved for sale in Europe.
CAUTION: The NeoChord device is not available for use in the United States.*